Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

0.8198 +0.0396 (+5.08%)
Streaming Delayed Price Updated: 10:02 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
3 Penny Stocks Set to Pass the $5 Mark Soon ↗
Here are three high potential penny stocks with recent news that could move them above the $5 mark in the next six to 12 months 
Via InvestorPlace
News headline image
3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗
Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning! 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
News headline image
Recap: Atossa Therapeutics Q2 Earnings ↗
  Atossa Therapeutics (NASDAQ:ATOS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:30 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyzing Atossa Therapeutics's Unusual Options Activity ↗
Atossa Therapeutics (NASDAQ:ATOS) shares experienced unusu... 
Via Benzinga
News headline image
7 High-Potential Penny Stocks in the Biotech Sector ↗
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
News headline image
3 Best Penny Stocks Under $1 to Buy in April ↗
By their very nature, the best penny stocks under $1 are a huge gamble with potentially huge returns for speculative investors. 
Via InvestorPlace
News headline image
The 3 Best Biotech Stocks Under $1 to Buy for April ↗
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider. 
Via InvestorPlace
News headline image
The 3 Best Biotech Stocks Under $1 to Buy for January ↗
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday's session, 49 companies made new 52-week lows. 
Via Benzinga
News headline image
Why Is NuZee Down By Over 21%: Here Are 38 Stocks Moving Premarket ↗
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares rose 46% to $6.98 in pre-market trading after jumping around 46% on Friday. The company recently said it expects unaudited... 
Via Benzinga
News headline image
20 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Cyren Ltd. (NASDAQ: CYRN) rose 31.1% to $2.32 in pre-market trading after the company entered into an agreement with Content Services Group to sell all equity interests in its legacy secure... 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers ContraFect (NASDAQ:CFRX) stock in... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Tenet Healthcare (NYSE:THC) stock r... 
Via Benzinga
News headline image
ATOS Stock Holders Should Mark Their Calendars for Oct. 7 ↗
Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal. 
Via InvestorPlace
News headline image
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden ↗
Atossa Therapeutics Inc (NASDAQ: ATOS) has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen to reduce... 
Via Benzinga
News headline image
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress ↗
Atossa’s Covid treatment is too little too late and I am concerned about the market size for Endoxiden. Avoid ATOS stock here. 
Via InvestorPlace
News headline image
Atossa Therapeutics Has a Steep Climb Ahead of It ↗
Atossa Therapeutics is popular with the Reddit crowd. However, ATOS stock doesn’t make the top 25 on the platform. Should you buy it anyway? 
Via InvestorPlace
News headline image
As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock ↗
No matter talked about by the Reddit set, despite its heavy short-interest, ATOS stock will likely fall lower rather than get squeezed 
Via InvestorPlace
News headline image
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now ↗
ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution. 
Via InvestorPlace
News headline image
With Zero Revenue, I Can’t Get Excited About Atossa ↗
ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation. 
Via InvestorPlace
News headline image
The Bear Case for Atossa Therapeutics Makes More Sense at This Time ↗
Investors have become wary of the risks surrounding Atossa's pipeline. That caution will continue pulling down ATOS stock. 
Via InvestorPlace
News headline image
Most Active Equity Options For Midday - Wednesday, Aug. 4 ↗
Top Tickers: AMD, AAPL, TSLA, AMC, PFE, NVDA, GM, FB, BABA, MRNA, F, SOFI, HOOD, MU, UBER, BA, ATOS, AMZN, ATVI, NIO. 
Via Talk Markets
News headline image
88 Biggest Movers From Yesterday ↗
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
News headline image
Investors Should Avoid High-Risk Atossa Therapeutics ↗
Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point. 
Via InvestorPlace
News headline image
63 Biggest Movers From Friday ↗
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.